Radiation therapy for choroidal melanoma

Finger, Paul T.

doi:10.1016/s0039-6257(97)00088-x

Cited by 287 publications

(197 citation statements)

References 163 publications

Supporting

Mentioning

183

Contrasting

Unclassified

Order By: Relevance

“…Owing to the nature of our study, we cannot exclude that at least some of these represent late recurrences of the first malignancy. 42 Additionally, 2 patients were reported to present a melanoma in the fellow eye. One of them was diagnosed 2 months after the primary diagnosis, so most likely represents a bilateral melanoma, 43 but we cannot exclude the possibility of metastatic disease to the fellow eye.…”

Section: Study Populationmentioning

confidence: 99%

Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis

Bartosch

Mondim

Healy

et al. 2016

American Journal of Ophthalmology

View full text Add to dashboard Cite

PURPOSE: To determine the risk of second primary neoplasms (SPNs) in subjects previously diagnosed with uveal melanoma (UM), including an analysis on whether radiotherapy is a risk factor to develop these SPNs.DESIGN: Retrospective cohort study. METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) 9 database, we identified patients diagnosed with UM as their first malignancy between 1973 and 2011 (n [ 3976). We obtained standardized incidence ratios (SIR) and excess absolute risks of SPNs on patients with UM compared to a reference population. Multivariate Cox regression models were used to evaluate the effect of radiotherapy in SPN risk.RESULTS: Sixteen percent (n [ 641) of the patients developed SPNs during a median follow-up of 83 months (range, 1-463 months). This represented an 11% excess risk compared to the reference population, mainly owing to a significantly increased risk of skin melanomas (SIR [ 2.93, 95% CI: 2.23-3.78) and kidney tumors (SIR [ 1.91, 95% CI: 1.27-2.76), primarily in those diagnosed between 30 and 59 years of age. The occurrence of second UM was also increased (SIR [ 16.90, 95% CI: 9.00-28.90), which likely includes recurrences misclassified as a second cancer. Radiotherapy was performed in 39% (n [ 1538) of the patients. Multivariate analysis revealed that this treatment was not an independent risk factor for SPNs (hazard ratio [ 1.06, 95% CI: 0.88-1.26, P [ .54).CONCLUSIONS: Patients with UM presented an 11% higher risk of SPNs compared to the reference population. Radiotherapy does not seem to be a risk factor. SPNs should be considered in the surveillance of UM. (Am J Ophthalmol 2016;165:54-64. Ó 2016 Elsevier Inc. All rights reserved.) P UBLISHED DATA ON SURVIVAL OF UVEAL MELAnoma demonstrate that more than half of the patients are long-term survivors. At 5 and 10 years, the survival rates range between 68%-82% and 57%-62%, respectively.

show abstract

Section: Study Populationmentioning

confidence: 99%

Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis

Bartosch

Mondim

Healy

et al. 2016

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…It involves fixing a discshaped radiation source on the sclera covering the tumour, and commonly used radioactive sources include cobalt-60, iodine-125, palladium-103 and ruthenium-106. Different low-energy sources are now in common use, and iodine-125 and ruthenium-106 are the most common used nuclides in North America and Europe, respectively (Finger 1997).…”

mentioning

confidence: 99%

“…Because the relative dose distributions are distinctly different for each nuclide used for plaque radiotherapy, the selection of a particular nuclide may influence local control rate and hence the metastatic rate (Finger 1997). In addition, most case series of patients treated with a single nuclide are limited to 100-300 patients, usually reflecting the experience of a single centre.…”

mentioning

confidence: 99%

Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients

Seregard

1999

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

ABSTRACT.Purpose: Most case series of patients managed by brachytherapy for uveal melanoma are small and survival data show considerable inter-study variation. The aim of this study was to summarise similarly structured case series by meta-analysis. Methods: A systematic review generated 5 similarly structured case series including survival data for 1,066 patients treated by ruthenium plaque radiotherapy for uveal melanoma. After assessing the inter-study clinical heterogeneity, data were weighed for study size and pooled. Results: Patient and radiotherapy characteristics were largely homogenous, but tumour size varied considerably between studies. The 5-year melanoma-related mortality rate was 6% for small and medium tumours (T1/T2) and 26% for large (T3) tumours. The 5-year and 10-year melanoma-related mortality rates for a balanced set of tumours with small, medium and large tumours being present in similar proportions were 14% and 22%, respectively. Conclusion: Case series of patients with uveal melanoma managed by brachytherapy may be pooled to increase sample size and study power. The present estimate of survival following ruthenium plaque radiotherapy compares favourably with previously summarised data of survival after enucleation for similarly sized tumours.

show abstract

“…Brachytherapy is a form of radiation therapy which involves placing small sealed radioactive seeds inside or adjacent to the tumor 7 , 8 . Studies have shown that, for most eye melanomas, the methods of using removable ophthalmic plaques loaded with brachytherapy sources are as effective as surgery (enucleation) 9 , 10 , 11 …”

Section: Introductionmentioning

confidence: 99%

“…Therefore, the design of the ophthalmic plaques and selection of the radionuclide for intraocular cancers has been the primary goal of the clinical studies for many investigators 15 , 16 , 17 . Several investigations based on Monte Carlo simulations or experimental techniques have been performed for dosimetry of choroidal melanoma, using different ophthalmic plaques containing various brachytherapy sources 9 , 15 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 …”

Section: Introductionmentioning

confidence: 99%

Gold nanoparticle‐based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye

Asadi

Vaezzadeh

Masoudi

et al. 2015

J Applied Clin Med Phys

View full text Add to dashboard Cite

The effects of gold nanoparticles (GNPs) in 125I brachytherapy dose enhancement on choroidal melanoma are examined using the Monte Carlo simulation technique. Usually, Monte Carlo ophthalmic brachytherapy dosimetry is performed in a water phantom. However, here, the compositions of human eye have been considered instead of water. Both human eye and water phantoms have been simulated with MCNP5 code. These simulations were performed for a fully loaded 16 mm COMS eye plaque containing 13 125I seeds. The dose delivered to the tumor and normal tissues have been calculated in both phantoms with and without GNPs. Normally, the radiation therapy of cancer patients is designed to deliver a required dose to the tumor while sparing the surrounding normal tissues. However, as the normal and cancerous cells absorbed dose in an almost identical fashion, the normal tissue absorbed radiation dose during the treatment time. The use of GNPs in combination with radiotherapy in the treatment of tumor decreases the absorbed dose by normal tissues. The results indicate that the dose to the tumor in an eyeball implanted with COMS plaque increases with increasing GNPs concentration inside the target. Therefore, the required irradiation time for the tumors in the eye is decreased by adding the GNPs prior to treatment. As a result, the dose to normal tissues decreases when the irradiation time is reduced. Furthermore, a comparison between the simulated data in an eye phantom made of water and eye phantom made of human eye composition, in the presence of GNPs, shows the significance of utilizing the composition of eye in ophthalmic brachytherapy dosimetry Also, defining the eye composition instead of water leads to more accurate calculations of GNPs radiation effects in ophthalmic brachytherapy dosimetry.PACS number: 87.53.Jw, 87.85.Rs, 87.10.Rt

show abstract

Radiation therapy for choroidal melanoma

Cited by 287 publications

References 163 publications

Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis

Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis

Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients

Gold nanoparticle‐based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye

Contact Info

Product

Resources

About